Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 20601.15%.

  • NewAmsterdam Pharma's EBITDA Margin fell 205439600.0% to 20601.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 626.66%, marking a year-over-year decrease of 345500.0%. This contributed to the annual value of 530.15% for FY2024, which is 7256100.0% up from last year.
  • Per NewAmsterdam Pharma's latest filing, its EBITDA Margin stood at 20601.15% for Q3 2025, which was down 205439600.0% from 91.26% recorded in Q2 2025.
  • NewAmsterdam Pharma's EBITDA Margin's 5-year high stood at 57.18% during Q3 2024, with a 5-year trough of 20601.15% in Q3 2025.
  • In the last 3 years, NewAmsterdam Pharma's EBITDA Margin had a median value of 1602.62% in 2023 and averaged 3789.75%.
  • Per our database at Business Quant, NewAmsterdam Pharma's EBITDA Margin surged by 54424000bps in 2024 and then tumbled by -205439600bps in 2025.
  • Over the past 3 years, NewAmsterdam Pharma's EBITDA Margin (Quarter) stood at 6163.76% in 2023, then skyrocketed by 88bps to 721.36% in 2024, then plummeted by -2756bps to 20601.15% in 2025.
  • Its EBITDA Margin stands at 20601.15% for Q3 2025, versus 91.26% for Q2 2025 and 1328.41% for Q1 2025.